Erschienen in:
17.11.2020 | COVID-19 | Letter to the Editor
Zur Zeit gratis
Use of DPP-4 inhibitors in patients with COVID-19
verfasst von:
Chia Siang Kow, Syed Shahzad Hasan
Erschienen in:
Acta Diabetologica
|
Ausgabe 2/2021
Einloggen, um Zugang zu erhalten
Excerpt
We read with interest the discussion by Solerte et al. [
1] on the various physiological processes on the immune system where dipeptidyl peptidase‐4 (DPP‐4) is involved. Besides, as hypothesized by the authors, the presence of DPP-4 in the respiratory tract may facilitate the entry of severe acute respiratory syndrome (SARS-CoV-2), the causative pathogen for coronavirus disease 2019 (COVID-19). Therefore, at first sight, it seems logical for the authors to propose that the use of DPP-4 inhibitors may be benficial in patients with COVID-19. …